Abstract
In sarcoidosis, chronic pulmonary aspergillosis (CPA) may be associated with significant morbidity, and treatment failure rates are often high, even with newer triazole antifungal agents. We report a treatment regimen of cyclical caspofungin infusions in 10 patients with sarcoidosis and worsening CPA despite oral triazoles.
Keywords:
Aspergillus Lung Disease; Sarcoidosis.
MeSH terms
-
Adult
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / therapeutic use*
-
Caspofungin
-
Chronic Disease
-
Echinocandins / administration & dosage
-
Echinocandins / therapeutic use*
-
Female
-
Follow-Up Studies
-
Humans
-
Immunocompromised Host
-
Infusion Pumps
-
Lipopeptides
-
Male
-
Middle Aged
-
Pulmonary Aspergillosis / complications*
-
Pulmonary Aspergillosis / diagnosis
-
Pulmonary Aspergillosis / drug therapy*
-
Pulmonary Aspergillosis / mortality
-
Sarcoidosis / complications*
-
Sarcoidosis / diagnosis
-
Sarcoidosis / drug therapy*
-
Sarcoidosis / mortality
-
Treatment Outcome
Substances
-
Antifungal Agents
-
Echinocandins
-
Lipopeptides
-
Caspofungin